ZHANG Rui,YAN Jingshun,JIA Fuyun,et al.Research progress on the improvement of myocardial fibrosis by traditional Chinese medicine through regulation of NLRP3 inflammasome[J].ZHONGGUO YAOFANG,2025,36(08):1008-1012.
ZHANG Rui,YAN Jingshun,JIA Fuyun,et al.Research progress on the improvement of myocardial fibrosis by traditional Chinese medicine through regulation of NLRP3 inflammasome[J].ZHONGGUO YAOFANG,2025,36(08):1008-1012. DOI: 10.6039/j.issn.1001-0408.2025.08.21.
Research progress on the improvement of myocardial fibrosis by traditional Chinese medicine through regulation of NLRP3 inflammasome
Myocardial fibrosis (MF), characterized by decreased cardiac function and myocardial compliance, is a pathological process and a progression factor in various cardiovascular diseases. The nucleotide-binding domain leucine-rich repeat and pyrin domain-containing receptor 3 (NLRP3) inflammasome is closely related to the development of MF. Recent studies have shown that traditional Chinese medicine (TCM) can regulate the NLRP3 inflammasome to alleviate MF. Based on this, this article systematically summarizes the research progress on the mechanisms by which TCM regulates the NLRP3 inflammasome to improve MF. It is found that active ingredients of TCM, such as alkaloids (lycorine,vincristine,bufalin), saponins (astragaloside Ⅳ,diosgenin,ginsenoside Rg
3
), terpenoids (celastrol,oridonin), and phenols (polydatin,curcumin,phloridzin) as well as TCM formulas (Zhachong shisanwei pills,Zhilong huoxue tongyu capsules, Luqi formula) can inhibit the activation of the NLRP3 inflammasome, thereby suppressing the release of inflammatory factors such as interleukin-1β and IL-18, reducing inflammatory damage to myocardial tissue, alleviating excessive deposition of the extracellular matrix, and thus exerting the effect of improving MF.
PAULUS W J , ZILE M R . From systemic inflammation to myocardial fibrosis:the heart failure with preserved ejection fraction paradigm revisited [J ] . Circ Res , 2021 , 128 ( 10 ): 1451 - 1467 .
XIE L L , WANG T Y , LIN S , et al . Uncaria rhynchophylla attenuates angiotensin Ⅱ-induced myocardial fibrosis via suppression of the RhoA/ROCK1 pathway [J ] . Biomed Pharmacother , 2022 , 146 : 112607 .
MANGAN M S J , OLHAVA E J , ROUSH W R , et al . Targeting the NLRP3 inflammasome in inflammatory di-seases [J ] . Nat Rev Drug Discov , 2018 , 17 ( 8 ): 588 - 606 .
DUAN Y H , WANG J H , CAI J , et al . The leucine-rich repeat(LRR)domain of NLRP3 is required for NLRP3 inflammasome activation in macrophages [J ] . J Biol Chem , 2022 , 298 ( 12 ): 102717 .
FU J N , WU H . Structural mechanisms of NLRP3 inflammasome assembly and activation [J ] . Annu Rev Immunol , 2023 , 41 : 301 - 316 .
DOWNS K P , NGUYEN H , DORFLEUTNER A , et al . An overview of the non-canonical inflammasome [J ] . Mol Aspects Med , 2020 , 76 : 100924 .
ELLIOTT E I , SUTTERWALA F S . Initiation and perpetua-tion of NLRP3 inflammasome activation and assembly [J ] . Immunol Rev , 2015 , 265 ( 1 ): 35 - 52 .
ZHOU Z F , ZHU X Y , YIN R H , et al . K63 ubiquitin chains target NLRP3 inflammasome for autophagic degradation in ox-LDL-stimulated THP-1 macrophages [J ] . Aging(Albany NY) , 2020 , 12 ( 2 ): 1747 - 1759 .
GUO H T , CALLAWAY J B , TING J P . Inflammasomes:mechanism of action,role in disease,and therapeutics [J ] . Nat Med , 2015 , 21 ( 7 ): 677 - 687 .
PAIK S , KIM J K , SILWAL P , et al . An update on the regulatory mechanisms of NLRP3 inflammasome activation [J ] . Cell Mol Immunol , 2021 , 18 ( 5 ): 1141 - 1160 .
MEYERS A K , ZHU X W . The NLRP3 inflammasome:metabolic regulation and contribution to inflammaging [J ] . Cells , 2020 , 9 ( 8 ): 1808 .
BRACEY N A , GERSHKOVICH B , CHUN J , et al . Mitochondrial NLRP3 protein induces reactive oxygen species to promote Smad protein signaling and fibrosis independent from the inflammasome [J ] . J Biol Chem , 2014 , 289 ( 28 ): 19571 - 19584 .
WEI X , LV Y , YANG C X , et al . Bufalin reduces myocardial infarction-induced myocardial fibrosis and improves cardiac function by inhibiting the NLRP3/IL-1β signalling pathway [J ] . Clin Exp Pharmacol Physiol , 2023 , 50 ( 8 ): 688 - 697 .
REN B , FENG J P , YANG N , et al . Ginsenoside Rg 3 attenuates angiotensin Ⅱ-induced myocardial hypertrophy through repressing NLRP3 inflammasome and oxidative stress via modulating SIRT1/NF-κB pathway [J ] . Int Immunopharmacol , 2021 , 98 : 107841 .
GAO R F , SHI H R , CHANG S C , et al . The selective NLRP3-inflammasome inhibitor MCC950 reduces myocardial fibrosis and improves cardiac remodeling in a mouse model of myocardial infarction [J ] . Int Immunopharmacol , 2019 , 74 : 105575 .
GAO R F , LI X , XIANG H Y , et al . The covalent NLRP3-inflammasome inhibitor oridonin relieves myocardial infarction induced myocardial fibrosis and cardiac remode-ling in mice [J ] . Int Immunopharmacol , 2021 , 90 : 107133 .
ZHANG Y L , CHENG X Z , WANG Y N , et al . Phlorizin ameliorates myocardial fibrosis by inhibiting pyroptosis through restraining HK1-mediated NLRP3 inflammasome activation [J ] . Heliyon , 2023 , 9 ( 11 ): e21217 .